We have experienced two cases of alpha-fetoprotein (AFP)-producing early gastric cancer. One patient was a 73-year-old man diagnosed as having an early gastric cancer type 0 I + IIa at 40 x 40 mm on the greater curvature of the lower body of the stomach. The histological findings showed that proliferation of a well-differentiated tubular adenocarcinoma with hepatoid pattern was massively invading to the middle layer of the submucosa, with positive lymph vessel, and lymph node metastasis. The other patient was a 76-year-old man diagnosed as having an early gastric cancer type 0 IIa + IIc at 25 x 25 mm on the anterior wall on the greater curvature of the antrum. The histological findings showed that proliferation of a small cell carcinoma was massively invading to the deep layer of the submucosa, with positive lymph vessel, and lymph node metastasis. AFP was immunohistochemically found in the tumor cells of these two cases. Both patients died from liver metastasis. AFP-producing early gastric cancer was concluded to be at high risk of liver metastasis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2739/kurumemedj.50.63 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ITGAX promotes gastric cancer progression via epithelial-mesenchymal transition pathway.
Front Pharmacol
January 2025
Ganjiang Chinese Medicine Innovation Center, Nanchang, China.
Gastric cancer is the fifth most common cancer and the fourth leading cause of cancer-related deaths worldwide, accounting for nearly 800,000 fatalities annually. ITGAX (Integrin alpha X) is closely associated with immune cells, such as macrophages and dendritic cells. Its involvement in gastric cancer was identified through an analysis of The Gene Expression Omnibus (GEO) database, which highlighted as one of four key gastric cancer-related genes.
View Article and Find Full Text PDFThe Clinical Value of the Combined Detection of Systemic Immune-Inflammation Index (SII), Systemic Inflammation Response Index (SIRI), and Prognostic Nutritional Index (PNI) in Early Diagnosis of Gastric Cancer.
J Inflamm Res
January 2025
Department of Clinical Laboratory, Jiangsu Cancer Hospital & Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, People's Republic of China.
Objective: Gastric cancer (GC) is a common malignant tumor of the digestive tract. Accumulating studies suggest that inflammation is linked with the pathogenesis of GC. The study delves into novel hematological inflammatory markers, such as systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and prognostic nutritional index (PNI), to explore their potential applications in early diagnosis of GC.
View Article and Find Full Text PDFA prospective and comparative study on improving the diagnostic accuracy of early gastric cancer based on deep convolutional neural network real-time diagnosis system (with video).
Surg Endosc
January 2025
Department of Gastroenterology, Lanzhou University Second Hospital, Lanzhou, Gansu Province, China.
Background: Endoscopic diagnosis of early gastric cancer (EGC) is a challenge. It is not clear whether deep convolutional neural network (DCNN) model could improve the endoscopists' diagnostic performance.
Methods: We established a DCNN-assisted system and found that accuracy of diagnosis is higher than endoscopists.
Predicting Postoperative Infection After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy with Splenectomy.
Ann Surg Oncol
January 2025
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Background: Hematologic changes after splenectomy and hyperthermic intraperitoneal chemotherapy (HIPEC) can complicate postoperative assessment of infection. This study aimed to develop a machine-learning model to predict postoperative infection after cytoreductive surgery (CRS) and HIPEC with splenectomy.
Methods: The study enrolled patients in the national TriNetX database and at the Johns Hopkins Hospital (JHH) who underwent splenectomy during CRS/HIPEC from 2010 to 2024.
One-year incidence of chemotherapy-induced peripheral neuropathy in oxaliplatin- or taxane-based chemotherapy: a multicenter, prospective registry study (MiroCIP study).
Expert Opin Pharmacother
January 2025
Department of Neurology, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba, Japan.
Background: Chemotherapy-induced peripheral neuropathy (CIPN) and its associated pain negatively affect patient outcomes and quality of life (QoL). The two-part MiroCIP study included interventional and prospective observational studies. Here, we report the latter, describing CIPN incidence, risk factors, and outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!